IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Hormonal disturbances in the GH-IGF-I axis are considered important for the deterioration of glycemic control in T1DM particularly in adolescents. In addition it may have direct implications on the development of insulin resistance and long-term complications.

The Investigators hypothesis is that low circulating IGF-I and compensatory hyper-secretion of GH, in the presence of peripheral insulin excess, results in increased local IGF-I expression explaining both the deterioration in metabolic control and the increased risk for microvascular complications. Correction of imbalance in circulating and tissue-specific levels of IGF-I could lead to both better early metabolic control and to prevention of early diabetic complications in type 1 diabetic (T1DM) patients.

Aim of the present study is to validate the microdialysis technique as a useable tool to predict local biological effects of IGF-1 and to understand the pharmacokinetics of local IGF-I actions after sc injection of Increlex in type 1 diabetic patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peter Bang
• Treatments: Mecasermin

Criteria

Inclusion Criteria:

1. Type 1 diabetes duration at least two years and assumed C-peptide negativity

2. Chronological age from 18 to 25 years

3. Tanner stage > 4 (Girls: Tanner B4 or more, Boys: Testis > 15 ml)

4. Levemir or Lantus as basal analogue or CSII

5. IGF-1 < -1.0 SDS and HbA1C < 73 mmol/mol with screening or within past three months

6. Written informed consent

Exclusion Criteria:

1. Development of hypoglycemia that can not be controlled with increased glucose infusion-rate